Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortizatization of Intangibles (2016 - 2024)

Historic Amortizatization of Intangibles for Akebia Therapeutics (AKBA) over the last 9 years, with Q4 2024 value amounting to $9.0 million.

  • Akebia Therapeutics' Amortizatization of Intangibles changed 0.0% to $9.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 7498.68%. This contributed to the annual value of $36.0 million for FY2024, which is 0.0% changed from last year.
  • As of Q4 2024, Akebia Therapeutics' Amortizatization of Intangibles stood at $9.0 million, which was down 0.0% from $9.0 million recorded in Q3 2024.
  • Akebia Therapeutics' Amortizatization of Intangibles' 5-year high stood at $9.1 million during Q1 2020, with a 5-year trough of $6.1 million in Q3 2020.
  • Its 5-year average for Amortizatization of Intangibles is $8.8 million, with a median of $9.0 million in 2021.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first plummeted by 3296.7% in 2020, then surged by 4754.1% in 2021.
  • Akebia Therapeutics' Amortizatization of Intangibles (Quarter) stood at $8.3 million in 2020, then grew by 8.44% to $9.0 million in 2021, then changed by 0.0% to $9.0 million in 2022, then decreased by 0.01% to $9.0 million in 2023, then changed by 0.0% to $9.0 million in 2024.
  • Its last three reported values are $9.0 million in Q4 2024, $9.0 million for Q3 2024, and $9.0 million during Q2 2024.